ID	DDInter2252
	Drug Type	biotech
	Protein Chemical Formula	C1970H3848N50O947S4
	Protein Average Weight	43500.000
	CAS Number	2019171-69-6
	Description	Pegcetacoplan is a complement inhibitor indicated in the treatment of paroxysmal nocturnal hemoglobinuria (PNH).[A235000,L34095] Prior to its FDA approval, patients with PNH were typically treated with the C5 inhibiting monoclonal antibody [eculizumab].[A235000] Patients given eculizumab experienced less hemolysis caused by the membrane attack complex, but were still somewhat susceptible to hemolysis caused by C3b opsonization.[A235000,A235005] Pegcetacoplan was developed out of a need for an inhibitor of complement mediated hemolysis further upstream of C5.[A235000,A235005] Pegcetacoplan is a pegylated C3 inhibitor that can disrupt the processes leading to both forms of hemolysis that threaten patients with PNH.[A235000] Pegcetacoplan was granted FDA approval on 14 May 2021.[L34095]
	ATC Classification	L04AA54
Sequences	None
Useful Links	DrugBank KEGG Drug Wikipedia